Sandra Levy
ARTICLES BY THIS AUTHOR
- 1/6/2020
Schnucks kicks off community-wide step challenge
Schnucks customers who log 50,000 steps or more now through Feb. 29 have a chance to win $100. - 1/6/2020
Alembic launches generic Temovate
Alembic's generic Temovate provides a short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. - 1/6/2020
Daiichi Sankyo debuts Enhertu
Enhertu is indicated for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. - 1/5/2020
Allergan reaches $300M settlement in Loestrin, Minastrin suit
Warner Chilcott and Watson subsidiaries will pay approximately $300 million under settlement agreements. - 1/5/2020
BestRx announces scripClip interface
PerceptiMed's scripClip is designed to speed up the prescription dispensing process at will-call. - 1/5/2020
CVS Pharmacy offers free prescription delivery throughout January
CVS Pharmacy customers can take advantage of a special free one- to two-day delivery offer this month. - 1/5/2020
Lannett launches 2 generics
Venlafaxine ER tablets, 150 mg and 225 mg, and lidocaine topical solution 4% had a market value of roughly $150 million and $17 million, respectively, for the 12 months ended November 2019. - 1/2/2020
Novadoz gets FDA nod for generic Uloric
The Febuxostat brand had a market value of over $430 million over the previous 12 months. - 1/2/2020
Adamas settles patent litigation dispute with Sandoz
Sandoz will be allowed to launch a generic version of Gocovri on March 4, 2030 or earlier under certain circumstances. - 1/2/2020
Daiichi Sankyo obtains FDA approval for Enhertu
Daiichi Sankyo's Enhertu provides a new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies.
